Organic Active Ingredients TRIZ Cases

Tertiary amine bicyclic compounds selectively inhibit DGKα/ζ to boost T cell activation while limiting off-target kinase effects.

A cell-penetrating anti-DNA antibody boosts triplex and nuclease editing frequency while limiting off-target effects through RAD51 inhibition.

Anti-transferrin receptor AOCs improve cardiac cell uptake and suppress PRKAG2 mRNA, addressing the genetic driver of PRKAG2 cardiac syndrome.

Formoterol promotes erythroid differentiation and mitochondrial biogenesis to treat anemia when standard erythropoiesis therapies fall short.

Synthetic TLR4 agonists broaden peptidoglycan recognition beyond NOD1/2, helping modulate gut microbiota and reduce GI inflammation.

Dual TrxR and DHFR inhibition by imidazolyl gold NHC compounds offers a targeted NSCLC treatment route with potent cytotoxicity.

A soluble VEGFR tyrosine kinase eye-drop formulation reaches posterior ocular tissues, avoiding frequent injections and lowering systemic toxicity.

Targeting NKB-expressing neurons in the nucleus accumbens reduces drug reward behavior by increasing signaling to the lateral hypothalamus.

A stabilized liquid nimodipine composition uses excipient and solvent ratios to limit degradation impurities while enabling higher-concentration dosing.

Novel heterocyclic compounds target LpxC to block lipid A biosynthesis and inhibit resistant gram-negative bacteria linked to pneumonia.

Alcohol-substituted imidazo[1,2-a]pyridines balance potent human NMT inhibition with improved cell permeability and metabolic stability.

Biomimetic HDL-like nanostructures improve nucleic acid uptake, avoid endosomal trapping, and enable targeted gene regulation with low toxicity.

A deep eutectic solvent keeps pharmaceutical agents liquid at ambient temperature without water, protecting sensitive compounds during delivery.

Non-canonical synthetic RNA enables DNA-free cell transfection and gene editing with lower toxicity, reduced mutation risk, and reliable expression.

C25 substituent changes in rifabutin analogs improve activity against M. abscessus, addressing weak efficacy of existing rifamycins.

Crystalline mesembrine salts and hydrates improve stability, dissolution consistency, and bioavailability for mental health therapies.

Mixed herbal extracts combined with docetaxel boost anticancer activity, suppress EGFR, and help address toxicity, resistance, and recurrence.

Dual EGFR and c-Met targeting with lazertinib plus amivantamab helps delay resistance in EGFR-mutant NSCLC while managing key adverse reactions.

Impedance sensing along an indwelling gastric tube tracks bolus passage to estimate stomach contents and guide safer enteral feeding decisions.

Indoline derivatives balance potent DDR1/DDR2 inhibition with lung retention and low systemic exposure for inhaled fibrosis treatment.

Combining testosterone with the Smoothened agonist SAG promotes oligodendrocyte formation and remyelination with a different path than immunomodulators.

Combining an anti-B7-H3 antibody-drug conjugate with ATR or ATM inhibitors boosts cancer cell suppression beyond single-agent therapy.

By binding inactive JAK2, 6-heteroaryloxy benzimidazole scaffolds avoid hyperphosphorylation resistance while improving potency and selectivity.

Novel Formula I antifungal compositions improve bioavailability and stability while treating azole- and echinocandin-resistant infections.

Linker-based ligand-drug conjugates improve tumor cell targeting and controlled cytotoxic release while limiting toxicity to normal cells.

A self-adhesive cytisine patch uses polymer matrices and a permeation enhancer to enable 24-hour delivery with fewer GI side effects.

Gi-biased piperidine ligands target MOP with KOP or NOP pathways to preserve analgesia while reducing opioid side effects.

A transfer-based whole blood process lowers residual amustaline after pathogen inactivation, enabling safer infusion without powered equipment.

A single C-peptide and bisphosphonate formulation targets bone loss and muscle wasting together to lower fracture risk in osteosarcopenia.

Selective THR-beta agonist compounds target liver metabolism to treat NASH and NAFLD while minimizing THR-alpha-linked cardiac and bone side effects.

Triazole-modified GalNAc linkers improve ASGPR binding and make oligonucleotide liver delivery more consistent through click-chemistry conjugation.

Novel piperazine cyclic ureas improve RIP1 inhibition while maintaining metabolic stability, helping block necroptosis and ferroptosis.

Selective 3α-hydroxy-17β-amide steroids target α4β3δ GABA A receptors to modulate brain excitability in CNS disorders.

Preloaded drug and diluent compartments mix on demand and inject in four steps, enabling reliable self-administration in emergencies.

Systematic substituent changes on imidazo[4,5-d]pyridazine create new TLR7/TLR8 agonists with flexible synthesis and cytokine induction.

BCN512 can be given before, during, or after radiation exposure to reduce fibrosis and support wound healing with prolonged tissue protection.

Selective deuteration of gamma-carbolines improves metabolic stability to treat residual psychosis symptoms with fewer off-target side effects.

Spirocyclic MAGL inhibitors use targeted ring and substituent changes to improve cellular activity and lipophilic efficiency.

Non-covalent heterocyclic crystals activate Nrf2 through Keap1 while reducing off-target protein interactions and heart failure risk.

Selective urea derivatives inhibit PI3Kα to suppress cancer growth while reducing wild-type pathway toxicity in normal tissues.

Co-administered bupropion inhibits dextromethorphan metabolism in extensive metabolizers, sustaining plasma levels with fewer doses.

Selective ALPK1 inhibition reduces pro-inflammatory cytokines and helps treat sepsis, cytokine storms, and related inflammation.

A bis-HCl tenapanor tablet with tartaric acid and propyl gallate improves dissolution across pH variation while maintaining stability.

A single-dose AAV2 vector with a modified capsid enables sustained aflibercept expression, reducing repeat eye injections and complications.

C25 piperazine and piperidine substitutions help rifabutin analogs overcome weak activity against non-tuberculous Mycobacteria, especially M. abscessus.

Mutation-selective pyrrolopyridinone compounds target EGFR exon 20 insertions and C797S while limiting wild-type EGFR activity and toxicity.

Dimethylglycine with amylopectin supports scalp metabolism and hair root strength to address hair loss with fewer side effects.

An osmogen, glidant, and granulated spray-dried dispersion prevent polymer gelation after water ingress, enabling faster capsule dissolution.

Single-stranded oligonucleotides target expanded CAG repeat RNA to improve splicing modulation, selectivity, affinity, and molecular stability.

By blocking BTK signaling, a fused pyrimidine compound reduces IgG and inflammatory cytokines to slow IgA nephropathy progression.